Skip to search formSkip to main contentSkip to account menu

Levobunolol

Known as: (S)-5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone, Levobunolol [Chemical/Ingredient], 1(2H)-Naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, (S)- 
A naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
The current study determined the relative affinities and selectivities of numerous β-adrenoceptor antagonists at the endogenous… 
1995
1995
The potential effects of anti-glaucoma drugs, such as levobunolol and timolol, on blood flow in the posterior segment of the eye… 
1995
1995
1. Marcusen P V. Contact dermatitis due to formaldehyde in textiles 1934-1958. Preliminary report. Acta Dermatovenereologica 1959… 
1995
1995
Hintergrund Patienten und Methoden Ergebnisse Schlußfolgerungen Background Patients and methods Results Conclusions 
Highly Cited
1994
Highly Cited
1994
Since the late 1970s, topical β‐adrenergic blockers have been the drugs of choice in treating ocular hypertension and associated… 
Highly Cited
1992
Highly Cited
1992
Evidence has been found suggesting that long-term therapy with topical antiglaucoma medications may decrease the success of… 
1990
1990
Gas chromatographic and mass spectrometric properties of cyclic methyl and n-butyl boronates of 13 beta blockers and… 
1987
1987
The ocular and systemic disposition of levobunolol (LBUN), an antiglaucoma agent, was studied in albino rabbits. After topical…